Feis Equities reports 5.08% stake in Drugs Made In America

Drugs Made In America Acquisition Corp. reports that Feis Equities LLC and Lawrence M. Feis beneficially own 1,232,775 Ordinary shares, representing 5.08% of the class.

Rhea-AI Filing Summary

Drugs Made In America Acquisition Corp. reports that Feis Equities LLC and Lawrence M. Feis beneficially own 1,232,775 Ordinary shares, representing 5.08% of the class. The filing cites 24,276,913 Ordinary shares outstanding as of May 14, 2026 from the issuer's 10-Q.

The Schedule 13G shows sole voting and dispositive power over the 1,232,775 shares for both reporting persons and is signed by Lawrence M. Feis.

Insights

Equity Ownership Analyst

Feis Equities LLC reports a 5.08% passive stake in DMAA.

The filing lists 1,232,775 shares beneficially owned and cites 24,276,913 shares outstanding as of May 14, 2026 from the issuer's 10-Q; the percentage is calculated from that outstanding figure. The reporting persons state sole voting and dispositive power over the disclosed shares.

Because this is a Schedule 13G disclosure of beneficial ownership, the holding is presented as passive under the filing's terms; subsequent filings could change the ownership picture.

Corporate Governance Specialist

Ownership is attributed to both an LLC and an individual via a joint filing agreement.

The cover rows identify Feis Equities LLC and Lawrence M. Feis with identical share counts and percentages; Exhibit A is a Joint Filing Agreement. The signature block shows the Managing Member and the individual signed on 06/25/2026.

This filing documents reported beneficial ownership and control attributes; any change in voting or dispositive power would require an updated filing.

Key Figures

Shares beneficially owned: 1,232,775 shares Percent of class: 5.08% Shares outstanding (issuer): 24,276,913 shares

3 metrics

Shares beneficially owned 1,232,775 shares Amount reported in Item 4(a)

Percent of class 5.08% Calculated using 24,276,913 shares outstanding as of <date>May 14, 2026</date>

Shares outstanding (issuer) 24,276,913 shares Issuer's 10-Q for period ending March 31, 2026 (as of May 14, 2026)

Key Terms

Schedule 13G, Beneficially owned, Sole Dispositive Power

3 terms

Schedule 13G regulatory

"Item 1 and cover lines identifying the filing as a beneficial ownership statement"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned regulatory

"Item 4(a) states 'Amount beneficially owned: 1,232,775'"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Dispositive Power regulatory

"Ownership table shows 'Sole Dispositive Power 1,232,775.00' for reporting persons"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Feis Equities LLC hold in Drugs Made In America (DMAA)?

Feis Equities LLC beneficially owns 1,232,775 Ordinary shares, equal to 5.08% of the class. This percentage is based on 24,276,913 shares outstanding as of May 14, 2026, cited from the issuer's 10-Q.

Does Lawrence M. Feis report voting control over the shares in DMAA?

Yes. The filing reports that Lawrence M. Feis has sole voting power and sole dispositive power over 1,232,775 shares, as shown in the ownership table and the Item 4 disclosure.

What date is used to calculate the 5.08% ownership figure for DMAA?

The percentage is calculated using the issuer's reported figure of 24,276,913 Ordinary shares outstanding as of May 14, 2026, as referenced in the Schedule 13G under Item 4(a)/(b).

Was the Schedule 13G for DMAA signed and when?

The Schedule 13G is signed by Lawrence M. Feis in two capacities—Managing Member of the LLC and as an individual—on 06/25/2026, as shown in the signature block.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 07:56 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Drugs Made In America Acquisition Corp.

(Name of Issuer)

Ordinary share ($0.0001 par value)

(Title of Class of Securities)

G2847J104

(CUSIP Number)

06/18/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G2847J104

1

Names of Reporting Persons

Feis Equities LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ILLINOIS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,232,775.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,232,775.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,232,775.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.08 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Type of Reporting Person: OO - Limited Liability Company

SCHEDULE 13G

CUSIP Number(s): G2847J104

1

Names of Reporting Persons

Lawrence M. Feis

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,232,775.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,232,775.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,232,775.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.08 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Drugs Made In America Acquisition Corp.
(b)	Address of issuer's principal executive offices: 420 LEXINGTON AVENUE, SUITE 1402, NEW YORK, NEW YORK 10170
Item 2.
(a)	Name of person filing: (i) Feis Equities LLC (ii) Lawrence M. Feis
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is: 1740 Waukegan Road Suite 206 Glenview, Illinois 60025
(c)	Citizenship: Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated hereto by reference for each Reporting Person.
(d)	Title of class of securities: Ordinary share ($0.0001 par value)
(e)	CUSIP Number(s): G2847J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,232,775
(b)	Percent of class: 5.08 - The percentage set forth in row 11 of the cover page for each Reporting Person is based on 24,276,913 Ordinary shares outstanding as of May 14,2026, as reported by the Issuer in its 10-Q filing for the period ending March 31, 2026, filed with the Securities and Exchange Commission on May 14,2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,232,775
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,232,775
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Feis Equities LLC

Signature:	Lawrence M. Feis
Name/Title:	Managing Member LLC
Date:	06/25/2026

Lawrence M. Feis

Signature:	Lawrence M. Feis
Name/Title:	Individual
Date:	06/25/2026

Exhibit Information

Exhibit A - Joint Filing Agreement